Tamtam Try Tamtam free
Orion Pharma logo

Orion Pharma account plan

Pharmaceuticals oncology pain treatment

At a glance

Orion is a Finnish pharmaceutical group in human and veterinary medicines and APIs: EUR 1,889.5 million FY2025 net sales, about 4,000 people.

Orion Corporation, headquartered in Espoo and listed on Nasdaq Helsinki, develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients, with R&D focused on oncology and pain. It sells in over one hundred countries through its own network in Europe and six Asia-Pacific countries and through partners elsewhere, and runs eight production sites (six in Finland, one in France, one in Belgium). FY2025 net sales rose 22.5% to EUR 1,889.5 million and operating profit 51.6% to EUR 631.6 million, driven by royalties on the prostate cancer drug Nubeqa® partnered with Bayer. Personnel was 4,029 at year-end 2025. A shares carry 20 votes and B shares one vote.

Business units

Strategic priorities

Grow Nubeqa® with Bayer
Nubeqa® royalties reached the highest tier in Q2 2026 and now track Bayer's market sales; Orion estimates its Nubeqa net sales could exceed EUR 1 billion by the end of the decade, relying on the 2033 basic patent.
Build the innovative pipeline
Advance ODM-212 (TEAD inhibitor), with Phase 2 readout expected in late 2027 and Phase 3 run by Orion itself, and the first biologic ODM-216, which entered Phase 1 in September 2026.
Geographic expansion
Strengthen Europe, expand in Asia Pacific including Japan, and establish US R&D and commercial operations, starting with a Boston team of "tens of people".
Sharper commercial organisation
From 1 January 2027 a new International Commercial Operations under Hao Pan covers all ex-US commercial activity, while generics move under Global Operations.
2024-2028 financial targets
Net sales CAGR of at least 8%, operating profit growing faster than sales, equity ratio of at least 50% and ROE of 25% or higher.

Latest results

In January-September 2026 net sales rose 24.1% to EUR 1,481.5 million and operating profit 65.2% to EUR 501.2 million. Q3 alone brought net sales of EUR 542.2 million (+28.1%) and operating profit of EUR 209.9 million (38.7% margin), with Nubeqa® at EUR 279.9 million as the highest royalty tier applied all quarter. Branded Products grew 10.8% in Q3 while Generics and Consumer Health fell 3.4%. On 20 October 2026 Orion raised its 2026 outlook to net sales of EUR 2,070-2,140 million and operating profit of EUR 730-790 million, excluding material milestones. It had a net cash position at 30 September 2026 (gearing -1.3%).

Investments and deals

R&D spending
R&D expenses were EUR 210.4 million in 2025 (11.1% of net sales) and EUR 168.2 million in 9M 2026 (+20.3%), with all projects running at once.
Darolutamide supply capacity
Part of the darolutamide API is moving to a European contract manufacturer and a US-based contract manufacturer to manage supplier risk; tablets remain made in Orion's own plant.
Cambridge R&D centre
A new R&D centre in Cambridge, UK, focused on biologics and large molecules, part of 2025 capex of EUR 112.9 million.
Licensing deals
Biosimilar licences from Shilpa (IV nivolumab) and Qilu (IV pembrolizumab) for Europe, with launches expected in the early 2030s, and the APORON® apomorphine spray licence from Criceto.
MSD opevesostat licence
MSD holds a global licence for opevesostat, with Orion eligible for up to USD 30 million development, USD 625 million regulatory and USD 975 million sales milestones plus royalties.

Challenges and risks

Dependence on Nubeqa® and Bayer
Bayer represented about EUR 808.9 million of 2025 revenue, and the predictability of Nubeqa® royalties is a stated risk.
US pharmaceutical tariffs
Tariffs on Nubeqa were expected from October 2026, minor for Q4, with a bigger impact expected in 2027.
Supply-chain and production risk
Risks include disruption of own production and supplier dependence, illustrated by the July 2026 water damage at Fermion's Hanko plant, which will weigh on Fermion's Q4 external sales.
Generics price competition
Tougher price competition and regulatory change weigh on generics, which fell 3.4% in Q3 2026 on many small declines.
R&D timing and failures
Partner Tenax's LEVEL Phase 3 trial of oral levosimendan missed its endpoints in 2026, and ODM-105 was terminated after failing Phase 2.

What leadership says

“We have not changed our strategy. On the contrary, our strategy has become a necessity.”

Liisa Hurme, President and CEO · Q3 2026 conference call, 28 October 2026

“we have a potentially best-in-class TEAD inhibitor in our hands”

Liisa Hurme, President and CEO · On ODM-212, half-year 2026 conference call, 17 July 2026

“almost half of Orion's revenue comes from innovative medicines after the first nine months”

Liisa Hurme, President and CEO · Q3 2026 conference call, 28 October 2026

“when you build resilience, there is, of course, some price to that”

René Lindell, CFO · On dual-sourcing darolutamide API, Q3 2026 conference call, 28 October 2026

Where a supplier can help

API capacity and contract manufacturing
Tied to the darolutamide supply investment and supply-chain risk: CDMOs, quality and supplier-qualification services help Orion add resilient capacity.
US build-up support
Tied to the geographic expansion priority: recruiting, regulatory, medical affairs and market access services for the Boston team preparing ODM-212 Phase 3.
Clinical development capacity
Tied to the pipeline priority and rising R&D spend: CROs, trial sites and biologics development partners for ODM-212, ODM-216 and the Cambridge centre.
Commercial operations reorganisation
Tied to the new International Commercial Operations from 2027: CRM, sales analytics and commercial excellence tools for a unified ex-US organisation.
Generics cost and service efficiency
Tied to generics price competition: supply planning, procurement and logistics tools for a business management calls "really about supply, price, and service level".

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Orion Pharma?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Orion Pharma

What does Orion Corporation do?

Orion is a Finnish pharmaceutical company that develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients, with R&D in oncology and pain.

What is Orion's revenue?

FY2025 net sales were EUR 1,889.5 million (+22.5%) and operating profit EUR 631.6 million. The 2026 outlook is net sales of EUR 2,070-2,140 million and operating profit of EUR 730-790 million.

How many employees does Orion have?

Orion had 4,029 people at the end of 2025; the average headcount in January-September 2026 was 4,174.

Who leads Orion?

Liisa Hurme is President and CEO, René Lindell is CFO, and Veli-Matti Mattila chairs the Board.

What is Orion's strategy?

Build a customer-driven portfolio, expand geographically in Europe, Asia Pacific and the US, and develop growth enablers, targeting net sales CAGR of at least 8% over 2024-2028.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)